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Background & aims: Visceral hypersensitivity is one feature of irritable bowel syndrome (IBS). 
Bacterial dysbiosis might be involved in activation of nociceptive sensory pathways, but there 
have been few studies of the role of the mycobiome (the fungal microbiome) in development of 
IBS. We analyzed intestinal mycobiomes of patients with IBS and a rat model of visceral 
hypersensitivity.  
Methods: We used internal transcribed spacer 1-based metabarcoding to compare fecal 
mycobiomes of 18 healthy volunteers with those of 39 patients with IBS (with visceral 
hypersensitivity or normal levels of sensitivity). We also compared the mycobiomes of Long 
Evans rats separated from their mothers (hypersensitive) with non-handled (normally sensitive) 
rats. We investigated whether fungi can cause visceral hypersensitivity using rats exposed to 
fungicide (fluconazole and nystatin). The functional relevance of the gut mycobiome was 
confirmed in fecal transplantation experiments: adult maternally separated rats were subjected to 
water avoidance stress (to induce visceral hypersensitivity), then given fungicide and donor 
cecum content via oral gavage. Other rats subjected to water avoidance stress were given soluble 
β-glucans, which antagonize C-type lectin domain family 7 member A (CLEC7A or DECTIN1) 
signaling via spleen associated tyrosine kinase (SYK), a SYK inhibitor to reduce visceral 
hypersensitivity, or vehicle (control). The sensitivity of mast cells to fungi was tested with 
mesenteric windows (ex vivo) and the human mast cell line HMC-1.  
Results: α diversity (Shannon index) and mycobiome signature (stability selection) of both 
groups of IBS patients differed from healthy volunteers, and the mycobiome signature of 
hypersensitive patients differed from that of normally sensitive patients. We observed 
mycobiome dysbiosis in rats that had been separated from their mothers compared with non-
handled rats. Administration of fungicide to hypersensitive rats reduced their visceral 
hypersensitivity to normal levels of sensitivity. Administration of cecal mycobiomes from rats 
that had been separated from their mothers (but not non-handled mycobiome) restored 
hypersensitivity to distension. Administration of soluble β-glucans or a SYK inhibitor reduced 
visceral hypersensitivity, compared with controls. Particulate β-glucan (a DECTIN-1 agonist) 
induced mast cell degranulation in mesenteric windows and HMC-1 cells responded to fungal 
antigens by release of histamine.  
Conclusions: In an analysis of patients with IBS and controls, we associated fungal dysbiosis 
with IBS. In studies of rats, we found fungi to promote visceral hypersensitivity, which could be 
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reduced by administration of fungicides, soluble β-glucans, or a SYK inhibitor. The intestinal 
fungi might therefore be manipulated for treatment of IBS-related visceral hypersensitivity. 
 
Key Words: mycobiota, dectin-1, immune response, yeast 
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Introduction 
Irritable bowel syndrome (IBS) is a highly prevalent, stress related functional 
gastrointestinal disorder that is characterized by the presence of abdominal pain with altered 
bowel habits. Although IBS is a heterogeneous disorder, abdominal pain is a common 
denominator in all patients and a major unmet clinical need.1-4  Increased sensitivity to distension 
of the gastrointestinal tract, so called visceral hypersensitivity, is observed in ~50% of patients 
and hypothesized to be an underlying pathophysiological mechanism.5 In animal models, gut 
mucosal mast cells and their mediator histamine were shown to mediate visceral hypersensitivity. 
These results were recently confirmed in clinical studies were part of the IBS patients responded 
favorably to histamine receptor antagonists ketotifen and ebastine.6-9 How mast cells become 
activated is only partly elucidated. In acute stress, peripheral corticotrophin releasing factor 
(CRF) was shown to trigger mast cell degranulation and consequent gut epithelial barrier 
dysfunction and visceral hypersensitivity.10, 11 In contrast, continued post-stress visceral 
hypersensitivity, which was also mast cell dependent, could not be reversed by CRF-receptor 
antagonist in a rat model.12 Moreover, clinical trials with such antagonists were unsuccessful.13, 14 
Due to gut barrier dysfunction, that was also evidenced in IBS patients, microbial antigens 
normally confined to the gut lumen become exposed.11, 15 Indeed, several Toll-like receptors 
relevant for bacterial  recognition as well as antimicrobial peptides were shown to be upregulated 
in IBS, and bacterial microbiome dysbiosis of the gut was broadly investigated as a peripheral 
trigger for complaints.16, 17 However, evidence linking bacteria to IBS complaints has been 
circumstantial and sometimes even conflicting.17, 18 Fungi are a minor component of the gut 
microbiota.19 This may explain why the possible role of fungi in IBS, except for a small set of 
early and methodologically limited studies20, was largely ignored so far. Despite low abundance, 
recent evidence indicated that resident fungi can play a role in inflammatory bowel disease.19, 21-24 
In addition, it was shown that fungi/fungal antigens are activators of mast cells.25, 26 Together this 
led us to assess the possible role of fungi (i.e. the mycobiome) in abdominal pain in a cohort of 
IBS patients and an animal model for IBS.  
We used an Internal Transcribed Spacer (ITS)-1 based barcoding approach to demonstrate 
gut mycobiome dysbiosis in hypersensitive IBS patients compared to normally sensitive patients 
and healthy volunteers. Next, we evaluated whether gut fungi can be a direct cause for abdominal 
pain by using the rat maternal separation model of stress-induced IBS-like visceral 
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hypersensitivity. Fungicide treatment was able to reverse visceral hypersensitivity and fecal 
transplantation studies showed functionally relevant mycobiome differences between maternal 
separated and non-handled rats. Altered mycobiome composition in maternal separated rats was 
confirmed by mycobiome analysis. Finally, we demonstrated that host recognition of fungi via 
the Dectin-1/Syk signaling pathway is essential for post stress visceral hypersensitivity.    
 
Material and Methods 
Patient characteristics and ethics statement     
Patient characteristics are given in Table 1. The IBS and healthy volunteer population 
included are subgroups of the Maastricht-IBS cohort, comprising 540 IBS patients and 205 
healthy controls. The patients represent a mixed population from primary to tertiary care with an 
established clinical diagnosis of IBS according to the Rome III criteria. Age, gender, medication 
use, mean anxiety, depression and symptom scores do not differ when compared to the total IBS 
cohort (data not shown). Depression prevalence scores ≥ 827 in healthy volunteers, hypersensitive 
IBS and normally sensitive IBS were 0%, 21.1% and 20.0% respectively, prevalence scores for 
anxiety were 16.7%, 31.6% and 30%. Dietary intake as assessed by a validated food frequency 
questionnaire was available for a subgroup of patients and all controls (supplementary Table S1). 
No differences were found between overall energy intake, and intake of total protein, fat, 
carbohydrates and fibres between hyper-and normosensitive patients. The reported intake was 
however significantly lower in the total group of IBS patients (hyper- plus normosensitive) when 
compared to healthy volunteers (data not shown). Subjects included in the cohort gave written 
informed consent prior to participation. The study protocol had been approved by the Maastricht 
University Medical Center Committee of Ethics and is executed according to the revised 
Declaration of Helsinki (59th general assembly of the WMA, Seoul, South Korea, October 2008). 
The Maastricht IBS cohort study has been registered in the US National Library of Medicine 
(http://www.clinicaltrials.gov, NCT00775060).  
 
Animals and ethics statement 
Long-Evans rats (Harlan, Horst, The Netherlands) were bred and housed at the animal 
facility of the Academic Medical Center (Amsterdam, The Netherlands) under conditions of 
controlled light (06:00–18.00 h), temperature (20–22 ºC) and humidity (45%). Non-handled and 
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maternal separated rats were always bred in the same room but never shared the same cage. 
Importantly, individually ventilated cages were only used during the post anti-fungal treatment 
and repopulation period in experimental protocol 2. During all experiments rats were housed in 
groups of 4-6 animals. Water and food were available ad libitum. All animal procedures were 
conducted in accordance with the institutional guidelines and approved by the Animal Ethical 
Committee of the AMC/University of Amsterdam (reference protocol number 100998).    
 
Results 
Mycobiome differences exist between healthy volunteers, hypersensitive IBS and normally 
sensitive IBS patients.  
We compared the fecal mycobiome of healthy volunteers, hypersensitive IBS patients and 
normally sensitive IBS patients. Figure 1A depicts the 30 most predominant species and shows 
that the human mycobiome is dominated by two yeasts; Saccharomyces cerevisiae and Candida 
albicans. In healthy volunteers, their combined presence was 57% of total reads. In IBS these 
species were even more predominant and added up to 76% and 83% in hypersensitive and 
normally sensitive IBS patients respectively. Statistical analysis on the combined two species 
showed no difference when comparing the two IBS subgroups with each other (Supplementary 
Figure 1) but we did observe statistical differences between healthy volunteers and IBS 
subgroups. This may explain the loss of mycobiome diversity in patients as calculated by the 
Shannon index that combines richness (number) and evenness (relative abundance) of species.28 
Figure 1B shows significantly higher Shannon diversity in healthy volunteers when compared to 
both of the IBS subgroups (hypersensitive and normally sensitive IBS, P<0.01 and P<0.001 
respectively). 
Bray Curtis dissimilarity of ITS data did not reveal well defined clusters to separate 
healthy volunteer and IBS sub-groups. However, a similar negative result was obtained when 
analyzing the 16S rRNA gene data set; Bray-Curtis analysis did not reveal overt differences in 
bacterial microbiome composition (Supplementary Figure 2). To further explore potential 
differences between healthy controls and IBS patients we then addressed the high dimensionality 
of the mycobiome with a stability selection approach.29 With this, data are repeatedly subsampled 
and variable selection, via elastic net classification model, is performed on each subsampled 
dataset. Figure 1C depicts the computed weights of species selected frequently when comparing 
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hypersensitive IBS patients to healthy volunteers. These species are truly associated with 
outcome and indicate that inter group mycobiome differences exist. The accuracy of the stability 
selection approach was confirmed by constructing a receiver operating characteristic curve 
(Figure 1D). Subsequent computations of the area under the curve (AUC) showed outstanding 
(i.e. AUC>0.9) discriminating quality. We also assessed differences between normally sensitive 
IBS and healthy volunteers, and hypersensitive IBS and normally sensitive IBS. The most robust 
markers of inter group differences are depicted in Supplementary Figure 3A-B. Corresponding 
receiver operating characteristic AUCs indicated good discriminating quality for these 
comparisons (Supplementary Figure 3C-D). Thus, there is altered community composition of the 
mycobiota in hypersensitive IBS when compared to healthy volunteers and normally sensitive 
IBS patients.  
 
Essential role of fungi in a rat model of stress-induced IBS-like visceral hypersensitivity.  
 To further examine the possible role of fungi, we used the well-established rat maternal 
separation model.7, 8, 12 We confirmed that water avoidance stress at adult age induces visceral 
hypersensitivity in maternal separated Long Evans rats whereas non-handled rats remained 
normally-sensitive (see vehicle treated rats in Figure 2A). To test the involvement of the 
mycobiome, two fungicides (fluconazole or nystatin) were administered to maternally separated 
rats for a three week period prior to water avoidance. Both fungicides independently prevented 
the occurrence of post-stress visceral hypersensitivity compared to vehicle in maternal separated 
rats (Figure 2A). Non-handled rats were not affected by fungicide treatment.  
The functional relevance of the gut mycobiome was confirmed in post water avoidance 
fungal depletion and fecal transplantation experiments (setup depicted in Figure 2B). Three 
separate groups of adult maternally separated rats were first subjected to water avoidance stress 
which caused post stress visceral hypersensitivity in all groups (Figure 2C). All rats were then 
treated with a combination of fluconazole and nystatin, resulting in amelioration of visceral 
hypersensitivity. Next, donor caecum content was administered by oral gavage. Prior to 
collection of this transplantation material, donor rats were subjected to colonic distension 
protocols to ascertain correct post water avoidance visceral sensitivity status (Supplementary 
Figure 4). Recipient group 1 was then supplemented with pooled caecum content of fungicide 
treated maternally separated donors. This procedure did not restore visceral hypersensitivity. In 
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contrast, in recipient group 2 the hypersensitive phenotype was re-induced when rats were 
gavaged with caecum content of maternally separated donors that were not treated with 
fungicides. In recipient group 3, donor material obtained from non-fungicide treated non-handled 
rats did not induce visceral hypersensitivity. Thus, fungicides reduce visceral hypersensitivity and 
transplantation of donor caecum content from non-fungicide treated maternally separated rats is 
able to re-establish the hypersensitive phenotype. These experiments provide strong evidence for 
a causal role of fungi in the etiology of visceral hypersensitivity and also suggest that relevant 
differences exist between the mycobiome of non-handled and maternally separated rats. 
 
The fecal mycobiome of maternal separated rats differs from non-handled rats.  
 Similar to the human mycobiome, we addressed possible differences between groups in 
our rat model by ITS1 based metabarcoding. We first confirmed a normal visceral sensitivity 
status of non-handled rats and post water avoidance hypersensitivity in maternally separated rats 
that was reversed upon fungicide treatment (Figure 3A). Fecal pellets of these rats were then used 
for mycobiome analysis. The Shannon diversity index indicated significantly higher alpha 
diversity in non-fungicide treated maternally separated rats compared to non-treated non-handled 
rats and fungicide treated maternally separated rats (Figure 3B). Beta diversity (i.e. compositional 
difference between samples) was then determined by unsupervised cluster analysis using Bray-
Curtis dissimilarity. This approach revealed distinct clusters corresponding to non-handled, 
maternally separated and fungicide treated maternally separated rats as depicted in the (left side) 
dendrogram of Figure 3C. The heat map in this figure shows the relationship between clustering 
and prevalence of the 20 most abundant fungal species. Together, these results confirm altered 
mycobiota composition in maternal separated rats that was already suggested by the fecal transfer 
experiments. In contrast, Bray-Curtis dissimilarity analysis of 16S rRNA gene data sets did not 
reveal well defined clusters to separate non-handled rats from maternal separated and 
fluconazole/nystatin treated maternal separation rats (Supplementary Figure 5). This lack of 16S-
based separation between pre- and post-fluconazole/nystatin treatment samples suggests that 
fungicide-induced analgesia in maternal separated rats was not driven by consequential bacterial 
microbiome changes.  
Mycobiome dissimilarities were further emphasized by stability selection results shown in 
Supplementary Figure 6. Depicted are the fungal biomarkers contributing to inter group 
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differences when comparing non-handled to maternally separated rats. Finally, to further 
strengthen the notion of strong dissimilarity between groups, we applied a co-regularized spectral 
clustering algorithm to the dataset.30, 31 A heatmap plot of the resulting co-occurance matrix is 
depicted in Figure 3D. Seven out of 8 of the non-handled rats fell within a separate cluster to the 
exclusion of the maternally separated rats and fungicide treated maternally separated rats. Within 
clusters, individual rats share similar mycobiome composition.  
Comparable to earlier findings22, 23, a number of species identified in rat feces was also 
observed in chow, but clear differences do exist (Figure 4A). Furthermore, while being on the 
same diet, non-handled and maternal separated rats displayed different relative species 
contributions (examples in Figure 4B-E), suggesting that chow is not the most important source 
of gut fungi. In Supplementary Table 2 we used the results of human and rat stability selections 
(depicted in Figure 1C and Supplementary Figure 6A respectively) to compare human and rat 
mycobiome composition on species level. Analogous to publications on the bacterial microbiome 
in other rodent models32 there is only partial overlap between human and rat mycobiota. 
Comparison at fungal class level confirmed partial overlap (Supplementary Figure 7). Thus, our 
rat model can be used for proof of principle studies where experimental manipulations address 
the possible role of fungi in post stress visceral hypersensitivity but other fungi may be involved 
in IBS pathophysiology. 
 
Fungal recognition via the Dectin-1/Syk signaling pathway is important in post water avoidance 
visceral hypersensitivity.   
We next sought to elucidate the mechanism by which fungi could affect the IBS 
phenotype. The C-type lectin receptor family is important in the recognition of fungi by the 
immune system. Several of these receptors signal through Syk-dependent pathways.33 The use of 
a specific Syk inhibitor resulted in reversal of visceral hypersensitivity after water avoidance 
(Figure 5A). An important Syk recruiting C-type lectin receptor is Dectin-1 that recognizes the 
fungal cell wall component particulate β-glucan, an interaction that can be antagonized by soluble 
β-glucans.34 High dose soluble β-glucans (50 mg/kg, applied 3 times within a 24 hour timeframe) 
prevented increase in visceral sensitivity after water avoidance stress, whilst vehicle and low dose 
(20 mg/kg) soluble β-glucan administration had no effect on hypersensitivity (Figure 5B). Next 
we investigated whether treatment with soluble β-glucans can also reverse visceral 
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hypersensitivity. Starting directly after water avoidance stress, we administered the 50 mg/kg 
dose during a 1 week treatment protocol (b.i.d gavage). Whereas vehicle treated rats remained 
hypersensitive, soluble β-glucans reversed post water hypersensitivity to distension (Figure 5C). 
Although involvement of ligand-receptor interactions other than β-glucan/Dectin-1 cannot be 
excluded, these findings do indicate the relevance of fungal recognition in the genesis of visceral 
hypersensitivity. Since the role of mast cells and histamine in preclinical models and part of IBS 
patients is now firmly established6-9, we next sought to confirm earlier reports on fungi/fungal-
antigen induced mast cell activation.25, 26 We used Texas-red labeled avidin to visualize 
degranulating mast cells in gut mesenteric windows. In contrast to incubation with control bovine 
serum albumin solution, particulate β-glucans induced mast cell degranulation (Supplementary 
Figure 8A-C). Moreover, when the Dectin-1 expressing mast cell line HMC-1 was incubated with 
heath inactivated C. albicans (2.5:1 ratio), histamine release-levels equaled those of 50 µg/ml 
compound 48/80 (Supplementary Figure 8D-E). Thus, we conclude that mast cells are indeed 
equipped to recognize fungi and respond with histamine release.   
 
 
Discussion 
 
 So far, investigations on the possible role of gut microbial communities in IBS almost 
exclusively focused on bacteria. Based on recent evidence that fungi can aggravate disease 
severity in colitis19, 21-24, we assessed the role of the gut mycobiome in IBS. We observed altered 
mycobiome composition in patients, which let us to assess the role of fungi in the maternal 
separation model for stress induced visceral hypersensitivity. Fungicide treatment of 
hypersensitive rats reversed the enhanced response to colonic distension. Subsequent fecal 
transplantations showed that only the maternal separation mycobiome was able to reconfer 
visceral hypersensitivity to fungicide treated maternal separation rats. Experimental evidence on 
the role of the Dectin-1/Syk pathway indicated that direct activation of the host immune system 
by fungal antigens is relevant for visceral hypersensitivity. Finally, we showed that mast cells are 
capable of histamine release upon stimulation with fungi.  
Our earlier investigations in the maternal separation model established an important role 
for mast cells and the histamine-1-receptor.7, 8 These results were confirmed in clinical trials6, 9, 
but triggers for mast cell degranulation remained elusive. In rat, it was shown that CRF receptor 
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antagonism can prevent acute stress-induced mast cell degranulation and resulting visceral 
hypersensitivity.10, 11 In contrast, post stress hypersensitivity to distension, although it was also 
mast cell dependent, could not be reversed by CRF receptor antagonist.12 Our present data 
suggest that continued visceral hypersensitivity is driven by cellular recognition of fungal β-
glucans that are normally confined to the gut lumen. Although we did not investigate mechanisms 
involved in the translocation of these antigens, an earlier publication by Ait-Belgnaoui et al. 
indicated that barrier dysfunction is a prerequisite for stress-induced hypersensitivity to 
distension. Using a partial restraint model it was shown that treatment with a tight junction 
blocker or a specific myosin light chain kinase inhibitor not only preserved barrier integrity under 
stress conditions, but also prevented the development of visceral hypersensitivity.35 Although not 
formerly shown, the authors suggested that stress-induced opening of tight junctions favors the 
uptake of luminal antigens, leading to activation of mucosal immune cells and subsequent 
sensitization of sensory afferents. Gut barrier dysfunction was repeatedly described in IBS patient 
studies11, 15 and the maternal separation model36, 37, indicating that similar mechanism may 
explain our results. Taken together, the above data suggest that post stress visceral 
hypersensitivity may be the result of a two-stage process (Figure 6). Upon acute stress (phase 1), 
peripheral CRF triggers mast cell degranulation and, consequently, afferent activation and barrier 
dysfunction. The latter facilitates uptake of fungal antigens like particulate β-glucans, and 
renewed mast cell activation leading to a ‘self-sustaining loop’ of continued barrier dysfunction 
and visceral hypersensitivity (phase 2). Importantly, fungi are considered gut commensals but 
may become life threatening pathogens in immunocompromised individuals. Successful anti-
fungal immunity can involve innate and adaptive responses.38, 39 Overt inflammation is absent in 
IBS and the rat maternal separation model.8, 40 Therefore, our data on the role of the Dectin-1/Syk 
pathway suggest a subtle but effective innate anti-fungal immune response that occurs at the cost 
of chronic pain. Regarding the proposed perpetual nature of phase 2, previous results indeed 
showed that maternal separated rats, when exposed to 1 hour of water avoidance stress, remained 
hypersensitive to distension for at least 1 month afterwords.12  
When treating rats with fungicides it is conceivable that this will also lead to bacterial 
microbiome changes that can be held responsible for the observed in vivo analgesic effect. 
However, 16S microbiome analysis did not show differences between pre- and post-fungicide 
treated maternal separation rats. In addition, our experiments on the role of fungal recognition via 
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the Dectin-1/Syk pathway suggested that not bacteria but fungi drive post stress visceral 
hypersensitivity. This is also relevant for the fecal transfer experiments where only transfer of  
non-fungicide treated maternal separation caecum content was capable of restoring visceral 
hypersensitivity in fungicide treated maternal separated rats. These experiments suggested that a 
specific mycobiome is required and comparison of maternal separated and non-handled fecal 
samples indeed showed separation-induced mycobiome dysbiosis. This result confirmed our 
observations in human where we found mycobiome differences between healthy volunteers and 
hypersensitive IBS, and between normally sensitive and hypersensitive patients. How a 
difference in mycobiome composition is relevant in relation to immune activation during fecal 
transfer was not addressed here. However, in a large set of clinical isolates, Odabasi et al. showed 
a wide range of (1→3)-β-d-glucan levels in fungal culture supernatants.41 Particulate β-glucans 
are known to ligate Dectin-1 and possibly increased numbers of high level β-glucan expressing 
species in donor feces of maternal separated rats can explain our results. Moreover, even under 
equal expression of β-glucans the exposure to the fungal cell surface can vary among different 
morphological forms and species.39 Relevant differences may also occur on strain level. In 2007, 
two papers with seemingly opposite results were published in Nature Immunology. One 
investigation showed that Dectin-1 was essential for controlling systemic infection with C. 
albicans in mice, the other found that Dectin-1 was not required.42, 43 In a follow up paper, these 
contradicting findings were shown to result from the usage of different strains of C. albicans.44 In 
this case the authors showed variations in adaptability to the immunological status of the host, 
resulting in substantial differences in cell wall architecture and innate immune recognition. Strain 
differences may also be relevant in the mycobiome specific visceral hypersensitivity shown in 
our repopulation experiments, but were not addressed in our mycobiome assessment. 
The reason for mycobiome dysbiosis in maternal separated rats remains elusive at this 
stage but may relate to changes in dam-pup interactions in the postnatal period and/or altered 
HPA-axis responsiveness that were described in this model. Their effect on the mycobiome was 
never investigated but both were shown to affect bacterial microbiome composition.45, 46 Diet was 
also evidenced to be an important regulator of mycobiome diversity47 but all rats were on the 
same chow. In contrast, dietary differences within and in between groups may explain why 
mycobiome dissimilarity between healthy volunteer and IBS subgroups was less pronounced than 
in rat. In mouse studies, antibiotics were also shown to induce mycobiome perturbations.48 Thus, 
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variable use of antibiotics may be another important factor leading to increased mycobiome 
heterogeneity within healthy volunteer and patient groups. To avoid short term antibiotics-
induced interferences healthy volunteers and patients were only included when not having used 
antibiotics and anti-fungals for a period of at least 3 months before sample collection. Yet, 
uncertainties like earlier antibiotics use and diet may explain why differences between human 
sample groups could be shown by stability selection but not by the unsupervised Bray-Curtis 
dissimilarity analysis that was used in rat data. Similar considerations may explain the absence of 
bacterial microbiome differences between normal control and patient groups. Clearly a future 
replication study in a separate cohort will be needed to confirm the correlation between IBS and 
mycobiome dysbiosis.  
Our data on fungal α-diversity showed contradicting results between rat and human. The 
Shannon diversity index indicated higher mean species diversity in healthy volunteers compared 
to IBS subgroups. In rat, not the normal but the IBS-like phenotype instead was associated with 
highest α-diversity. This discrepancy possibly arises due to the relative overabundance of S. 
cerevisiae and C. albicans in all human samples. The observed shift in their presence may have 
impacted α-diversity in IBS samples and such over representation of a limited set of fungal 
species was not observed in rat. In line with our observations, Sokol et al. found higher fungal α-
diversity in fecal samples of healthy volunteers compared to inflammatory bowel disease 
patients.24 DSS colitis in mouse however, showed no significant differences in α-diversity 
between normal and colitic mice.23 Another factor contributing to discrepancy in human/rat α-
diversity may be that, similar to the rodent bacterial microbiome, there is only partial overlap 
between rat and human fecal mycobiota. This also complicates predictions on the translational 
value of the current investigations in rat. Similar considerations apply to pre-clinical microbiome-
related investigations in colitis models32 Nevertheless, a role of the microbiome in inflammatory 
bowel disease is now widely accepted.  
In line with bacterial microbiome investigations in IBS our human data set only provides 
an association between mycobiome dysbiosis and phenotype, not a causal link.49 Whether the IBS 
patient mycobiome is capable of inducing visceral hypersensitivity may be addressed by future 
‘human to rat’ fecal transfer experiments. So far, such an IBS-related colonization approach was 
only described in one publication where fecal suspensions of healthy volunteer and 
hypersensitive IBS patients were used to inoculate germ free Fischer 344 rats.50 Rats with an IBS 
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microbiome showed significantly higher response to distension than those inoculated with 
healthy volunteer fecal suspension. Focus in this investigation was on the possible role of the 
bacterial microbiome. Post-colonization treatment with anti-fungals to reverse transfer-induced 
hypersensitivity was not performed but should be included in future experiments. Importantly 
however, successful colonization of ‘normal’ germ free rats with IBS mycobiota may not be 
enough to obtain proof of principle. Our own observations showed a role for fungi in maternal 
separated rats and possibly these fungi play a role in predisposed animals only. In relation to this, 
De Palma et al. investigated the gut microbiome in relation to altered behavior. Colonization of 
adult germ free maternal separated mice lead to anxiety-like behaviour and behavioural despair 
whereas colonization of germ free non-handled mice did not.51 Possibly host factors present in 
maternal separated but absent in non-handled rats will also determine whether colonization with 
patient mycobiota leads to visceral hypersensitivity.  
We showed that mycobiome dysbiosis and immune recognition of fungal antigens play an 
important role in visceral hypersensitivity in rat. Although we also found fungal dysbiosis in IBS 
patients there is no evidence for causality at this point. Proof of principle in human may be 
obtained by performing a well conducted clinical trial with fluconazole or nystatin. Due to 
increased resistance of pathogenic fungi, these classical fungicidals should probably not be used 
for regular IBS therapy but are best reserved for highly invasive and often lethal fungal 
infections. More subtle approaches of mycobiome modulation may however be suitable for IBS. 
This could include the use of probiotic fungal and bacterial strains able to induce a favorable 
mycobiome shift. In addition, our investigations with soluble β-glucans in rat suggest that 
targeting of fungal immune recognition instead of fungi is possible, even with a mild treatment 
protocol. For most optimal results in patients however, combined treatment with CRF receptor 
antagonists may be needed. From the present investigations we conclude that the gut mycobiome 
may be relevant for abdominal pain in IBS and should be addressed in future investigations.   
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Figure legends 
 
Figure 1. Differences in mycobiome between healthy volunteers (HV), hypersensitive 
irritable bowel syndrome (IBS-H) and normally sensitive IBS (IBS-N) patients. (A) Pie 
charts show distribution of the 30 most abundant species (+1 segment ‘others’) in HV, IBS-H and 
IBS-N respectively. (B) Shannon diversity index comparing fecal mycobiome of HV, IBS-H and 
IBS-N showing median and 25-to-75% and 2.5%-to-97.5% percentiles. N=16-20/group, 
**P<0.01, ***P<0.001 (Mann-Whitney). (C) Most robust biomarkers (in weight factors) 
resulting from stability selections conducted on annotated fungal ITS-1 gene sequences 
comparing IBS-H to HV. (D) Receiver operating characteristic (ROC) corresponding to stability 
selection, the computed area under the curve shows outstanding discriminating quality 
(AUC>0.9, p<0.01). 
 
Figure 2. Fungi are important for water avoidance (WA)-induced visceral hypersensitivity 
of maternal separated (MS) rats. (A) Prevention of water avoidance-induced visceral 
hypersensitivity in maternal separated rats. Visceral sensitivity status is depicted by area under 
the curve of the relative response to colorectal distension (CRD). Prior to water avoidance, 
maternal separated and nonhandled (NH) rats received a 21 day treatment with vehicle alone, 
fluconazole or nystatin (n=8-9/group). (B) Schematic representation of fungal depletion and 
subsequent repopulation experiments (detailed in online methods). (C) Relative response to 
distension of three groups of maternal separated rats (n=8/group). After fluconazole/nystatin-
mediated reversal of post-water avoidance visceral hypersensitivity, group 1 received pooled 
donor caecum content obtained from fluconazole/nystatin treated maternal separated rats. Group 
2 received caecum content from non-treated maternal separated rats. Group 3 received caecum 
content from non-fluconazole/nystatin treated nonhandled rats. All data are mean +/- SEM, 
*P<0.05 (Wilcoxon signed rank).  
 
Figure 3. Differences in mycobiome between nonhandled (NH) and maternal separated 
(MS) rats. (A) Visceral sensitivity status of rats used in the mycobiome evaluations depicted by 
area under the curve of the relative response to colorectal distension (data are mean ± SEM). (B) 
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Box and whiskers plot showing Shannon diversity index comparing fecal mycobiome of NH, MS 
and flucanosole/nystatin treated MS (MS-F/N) rats. The line inside boxes represents median, the 
width of the boxes and whiskers represents the 25-to-75% and 2.5-to-97.5% percentiles. (C) Left 
side dendrogram shows results of unsupervised cluster analysis based on Bray-Curtis 
dissimilarity. Right side; heat map of individual rats depicting relative abundance (%) of the 20 
most abundant species. (D) Co-occurrence matrix of clustering rats. The more similar the 
mycobiome, the higher the tendency to cluster together. Co-occurrence values range from 0.0 
(dark blue for rats who never cluster together) to 1.0 (dark red for rats who always cluster 
together). Rat numbers on axes are symmetric and represent individual rats. N=7-8, *P<0.05, 
**P<0.01 (Mann Whitney and Wilcoxon signed rank). 
 
Figure 4. Mycobiome composition of rat feces and feed, and differences between selected 
fungal species. (A) Relative contribution species breakdown of the 20 most abundant fungal 
species in feed, nonhandled (NH), maternally separated (MS), and fluconazole/nystatin (F/N)-
treated maternally separated rats. (B-E) Examples relative contribution of different species in rat 
feces (B) Monographiella nivalis is lower in maternally separated rats and further diminished in 
F/N treated maternally separated rats.  (C-E) Acremonium zeae, Fusarium poae and uncultured 
Ascochyta all high in maternally separated and diminished upon F/N treatment. N=7-8, *P<0.05, 
**P<0.01, ***P<0.001 (Mann Whitney).     
 
Figure 5. Fungal recognition via the Dectin-1/Syk signaling pathway is important in post 
water avoidance (WA)-stress visceral hypersensitivity. (A) Schematic representation of the 
experimental set-up and relative response to colorectal distension (CRD) after post-water 
avoidance treatment with vehicle alone or Syk inhibitor (1, 10 or 30 mg/kg). (B) Experimental 
set-up and relative response to colorectal distension of a peri-water avoidance, soluble β-glucan 
(SBG) administration protocol (three times gavage/24 hours of vehicle, 20 mg soluble β-
glucan/kg or 50 mg soluble β-glucan/kg). (C) Experimental set-up and relative response to 
colorectal distension of a 1 week post- water avoidance, soluble β-glucan treatment protocol 
(vehicle alone or 50 mg soluble β-glucan /kg b.i.d.). Data are mean ± SEM. N=8-9/group, 
*P<0.05, **P<0.01 (Wilcoxon signed rank). 
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Figure 6. Proposed mechanism of the role of fungi in stress-induced visceral 
hypersensitivity in maternal separated rats. Previously, a key role for mast cells and the 
histamine-1 receptor (H1R) was evidenced in the maternal separation model. Initial stress-
induced mast cell degranulation and subsequent afferent activation and barrier dysfunction (phase 
1) were shown to depend on peripheral Corticotrophin Releasing Factor (CRF). Our current 
investigations show that the prolonged post-stress pain response (phase 2) depends on the 
presence and recognition (via Dectin-1/Syk) of a unique mycobiome and related uptake of 
particulate β-glucans. 
 
Table 1. Baseline characteristics of IBS patients and healthy volunteers used for fecal 
mycobiome analysis. a) Rectal sensitivity was assessed using an electronic rectal barostat 
procedure according to a standardized protocol. A VAS-score for pain≥20 mm at pressure step 26 
mmHg was used as cut-off to define visceral hypersensitivity.48 b)Lactose-free diet; c)assessed 
on a 5-point Likert scale; *p<0.05, **p<0.01 ***p< 0.001 as tested by Chi2 for dichotomous and 
ANOVA for continuous variables; #) p<001 between IBS-H and IBS-N. ##) within 3 months 
prior to sample collection.  
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 Hypersensitive
a
 
IBS n=19 
Normosensitive 
IBS n=20 
Healthy 
controls n=18 
Age (mean±SD years) 
Gender (% females) 
IBS subtype* 
   IBS-C 
   IBS-D 
   IBS-M 
   IBS-U 
Current smoker (%) 
Alcohol use >14  
   units/week (%) 
BMI (mean±SD kg/m2) 
HADS Depression-score (mean±SD)
**
 
HADS Anxiety score (mean±SD)
**
 
 
Medication use (%) 
   PPIs* 
   NSAIDs 
   SSRIs* 
   Motility altering drugs** 
Antibiotics/antifungal (%)
##
 
Diet (%) 
Pro/prebiotics (%) 
 
Symptom score (mean±SD of 14-day 
diary)
c
 
   Abdominal pain*** 
   Abdominal discomfort*** 
   Bloating*** 
   Belching
**/#
 
   Nausea
**/#
 
   Flatulence*** 
   Constipation
**/#
 
   Diarrhea
**/#
 
   Overall symptom burden*** 
 
Pressure step for first VAS score pain 
> 10mm (mean±SD mmHg)
***/#
 
40.3±18.3 
14 (73.7%) 
 
4 (21.1%) 
3 (15.8%) 
11 (57.9%) 
1 (5.3%) 
5 (26.3%) 
1 (5.3%) 
 
22.7±3.5 
4.4±3.8 
6.9±5.1 
 
 
6 (31.6%) 
2 (10.5%) 
6 (31.6%) 
7 (36.8%) 
- 
1 (5.3%)
b
  
- 
 
 
 
2.6±0.8 
2.8±0.8 
2.5±0.8 
1.8±0.7 
2.1±1.2 
2.5±0.9 
1.8±0.7 
1.6±0.7 
2.8±0.7 
 
13.0±8.7 
44.2±17.6 
14 (70.0%) 
 
5 (25.0%) 
10 (50.0%) 
3 (15.0%) 
2 (10.0%) 
5 (20.0%) 
1 (5.0%) 
 
25.4±4.5 
4.7±3.4 
6.3±3.6 
 
 
5 (25.0%) 
1 (5.0%) 
1 (5.0%) 
2 (10.0%) 
- 
- 
1 (5.0%) 
 
 
 
2.2±0.8 
2.3±0.7 
2.1±1.0 
1.5±0.6 
1.8±1.0 
2.5±1.2 
1.4±0.5 
1.3±0.3 
2.3±0.7 
 
37.6±10.9 
41.5±16.8 
12 (66.7%) 
 
- 
- 
- 
- 
1 (5.6%) 
2 (11.1%) 
 
23.8±4.6 
1.4±2.0 
2.9±3.0 
 
 
- 
- 
1 (5.5%) 
- 
- 
- 
1 (5.6%) 
 
 
 
1.1±0.2 
1.1±0.2 
1.2±0.2 
1.1±0.3 
1.0±0.0 
1.4±0.4 
1.1±0.2 
1.1±0.1 
1.1±0.2 
 
42.3±9.0 
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Supporting documents to: 
 
 
 
Intestinal Fungal Dysbiosis Associates With  
Visceral Hypersensitivity in Patients With 
 Irritable Bowel Syndrome and Rats  
 
  
  
 
 
This document includes: 
- Material and Methods 
-Supplementary figures 1-15 
-Supplementary tables 1 & 2  
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MATERIAL AND METHODS 
Maternal Separation 
Neonatal maternal separation in Long Evans rats predisposes for stress-induced visceral 
hypersensitivity at adult age.1, 2 This model mimics early adverse life events shown to be 
associated with increased risks of IBS later in life.3 Maternal separation was carried out as 
follows; on postnatal day 2, female pups were removed from the litter and dams were separated 
from remaining pups 3 hours daily for a 12 day period (postnatal day 2 to 14) by placing the 
dams in another room. During separation the cage with litter was placed on a heating mat to 
maintain pup body temperature. Pups were weaned at day 22. Non-handled pups were nursed 
normally.   
 
Colonic distension protocol and water avoidance (WA)  
Distensions were performed at the minimum age of 4 months with a latex balloon 
(Ultracover 8F, International Medical Products BV, Zutphen, The Netherlands) and carried out as 
described previously.2 The balloon catheter was inserted under short isoflurane anesthesia and, 
after a 20 min recovery period colonic distension was achieved by inflation of graded volumes of 
water (1.0, 1.5, and 2.0 mL) into the balloon. Length and diameter of the balloon during a 2 mL 
maximum volume distension were 18 and 15 mm, respectively. After each 20 sec distension 
period the volume of water was quickly removed and an 80 sec resting period was introduced. 
For acute stress at adult age (i.e. WA), rats were positioned on a pedestal (8 · 8 · 10 cm) attached 
to the bottom of a plexiglass tank (25 · 25 · 45 cm). The tank was filled with fresh tap water at 
room temperature (21 ºC) within 1 cm of the top of the pedestal and rats remained in the tank for 
1 hour. 
  
Measurement of the visceromotor response to colonic distension and data analysis 
Visceral hypersensitivity in patients is assessed by rectal distensions: hypersensitive IBS 
patients perceive pain during luminal distensions at lower volumes or pressures than normal 
controls. Pain scores are often evaluated by self-rating questionnaire (i.e. visual analogue score) 
that cannot be assessed in rats. However, colorectal distension in rat leads to reproducible 
contractions of abdominal musculature; the so called visceromotor response and the 
quantification of these contractions by electromyography (EMG) is often used to assess visceral 
pain.4 In short, a telemetric transmitter was sutured in the abdominal cavity to record EMG 
signals from two connected electrodes placed in the abdominal muscles as described earlier.2 
During distensions, animals were placed in a standard macralon cage that was positioned on top 
of an equally sized flat receiver (DSI). The receiver was linked to a Biopac MP100 data 
acquisition system (Biopac Systems Inc., Santa Barbara, CA, USA) and a personal computer via 
a raw data analog converter (Data Sciences International). Data were acquired with 
AcqKnowledge software (Biopac Systems Inc.) and then analyzed. Briefly, each 20 sec 
distension period and its preceding 20 sec of baseline recording were extracted from the original 
raw EMG data file. After correction for movement and breathing, data were rectified and 
integrated. Absolute datasets were then obtained by subtracting the 20 sec baseline recording 
from the 20 sec distension result. Similar to our previous publications final results were evaluated 
from normalized data sets, which were calculated from the absolute data by setting the 2 mL 
value of the first distension at 100%. The area under the curve of these relative responses was 
calculated for individual rats and used for statistical analyses by Wilcoxon-signed ranks test 
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(performed with SPSS for Windows, version 16.0; SPSS Inc., Chicago, IL, USA). Corresponding 
per volume line diagrams are given in Supplementary Figures 9-15.   
  
In vivo experiments 
Pre-water avoidance anti-fungal treatment. The drinking water of adult rats was 
supplemented with fluconazole (0.5 mg/ml), nystatin (200 U/ml) or vehicle alone (i.e. 
demineralized water) for 3 consecutive weeks. Just prior and directly after anti-fungal treatment 
(day -21 and day 0 respectively), the response to distension was assessed to exclude direct 
fungicide induced effects on baseline (pre-WA) sensitivity to distension. Directly after the second 
distension protocol rats were subjected to WA (day 0) and a third round of colorectal distensions 
on day 1.  
 
Post-water avoidance anti-fungal treatment and subsequent fungal repopulation 
(schematic representation in Figure 2B). The response to distension was assessed pre- and 24 
hours post-WA in 3 groups of MS rats. Next, all groups were treated with anti-fungals 
(combination treatment; 0.25 mg fluconazole/ml & 200 U nystatin/ml) in drinking water for 3 
consecutive weeks and then transferred (day 21) to individually ventilated cages until the end of 
the experiment. During the last 3 days of a 7 days fluconazole/nystatin washout period all groups 
received omeprazole (25 mg/kg daily). Post fungicide-treatment response to distension was then 
assessed at day 28. Directly after this, rats were gavaged with 1 ml fresh caecum content that was 
pooled from N=4-5 donor rats, pushed through a stainless steel wire mesh filter and diluted 1:1 
with water. Prior to being used as donor in these experiments all donor rats were evaluated for 
pre- and post-WA sensitivity status (for results see Supplementary Figure 2). In recipient rats, 
group 1 received caecum content of MS donor rats that were treated with fluconazole/nystatin for 
three weeks. Recipient group 2 received caecum content of non-fungicide treated MS donor rats 
and group 3 received pooled content of non-fungicide treated NH donors. All 3 recipient groups 
were then subjected to a second WA (at day 35) and a final distension protocol at day 36.  
 
Post-water avoidance treatment with Syk inhibitor (schematic representation in Figure 
5A). The response to distension was assessed in 4 groups of MS rats pre- and 24 hours post-WA. 
Directly after WA, rats received 1 oral gavage with vehicle alone (1% methylcellulose solution in 
water; group 1) or Syk inhibitor (GSK143, kind gift from GSK, Stevenage, UK; 1, 10 or 30 
mg/kg; groups 2, 3 and 4 respectively)5 and were subjected to a final distension protocol 24 hours 
post WA.   
 
Peri-water avoidance treatment with soluble β-glucans (schematic representation in 
Figure 5B). Directly after recording the first response to distension at 12.00 hrs, 3 groups of MS 
rats were gavaged with either vehicle alone (demineralized water) or soluble β-glucan (SBG, kind 
gift from Biotech Pharmacon ASA, Tromsø, Norway; 20 or 50 mg/kg). 3 hours later rats were 
subjected to WA, and gavaged again directly after. The final gavage was given the next morning 
at 09.00 hrs and response to distension was assessed at 12.00 hrs. 
 
Post-water avoidance treatment with soluble β-glucan (schematic representation in 
Figure 5C). The response to distension was assessed pre-WA (day 0) and 24 hrs post WA (day 1) 
in 2 groups of MS rats. During the next 7 days rats were gavaged twice daily (at 09.00 and 17.00 
hrs) with vehicle alone or 50 mg soluble β-glucan /kg. On day 8, response to distension was again 
assessed in both groups of rats.        
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Fecal pellet/stool collection 
Human stool samples were collected at home, brought to the lab and frozen within 24 
hours after defecation. Rat fecal pellets were collected directly from the anus just prior to 
distension protocols. All samples were stored in -80 0C until use. 
 
DNA extraction 
Rat and human fecal samples were resuspened in Tris-EDTA buffer (pH7.5) containing 
1.2 mM sorbitol, 250 U/ml lyticase and 0.2% β-mercaptoethanol. After 1 hour incubation at 
37ºC, pellets were spun down and taken up in Tris-EDTA lysis buffer with 2% T-X-100 and 8M 
guanidine thiocyanate.  This mix was incubated at room temperature for 4 hours, spun down and 
incubated with silica suspension to complex liberated DNA. Upon centrifugation complexes were 
washed with guanidine thiocyanate buffer (twice), 70% ethanol (twice) and acetone (twice), dried 
and eluted in aqueous low-salt buffer. Finally, cetyltrimethylammonium bromide (2% CTAB, 20 
minutes, 65 ºC) incubation and subsequent chloroform/iso-amyl alcohol extraction were used for 
final DNA purification. Remaining DNA was precipitated by isopropanol/sodium acetate, 
washed and stored in TE buffer until use.  
  
Sequencing of fungal ITS amplicons 
Barcoded fungal internal transcribed spacer regions (ITS) amplicons were generated using 
a two-step PCR approach. Fungal ITS 1 regions were first amplified with the following primers: 
forward 5′-CTTGGTCATTTAGAGGAAGTAA-3′ and reverse 5′- 
GCTGCGTTCTTCATCGATGC-3.6 Each reaction contained 300 times diluted and purified fecal 
DNA, hot start PCR master mix (Thermo Scientific) and nuclease free PCR grade water to a 50 
µl final reaction volume. PCR reactions consisted of an initial denaturation step of 95 °C, for 5 
min and 30 amplification cycles (95 °C  for 30 sec),  annealing  (52  °C for 45 sec) and 
elongation (72 °C for 1 min) and final extension step ( 72 °C for 10 min) followed by cool down 
(10 min at 4 °C). A negative control (blank) was included for each 24 PCR reactions. Next a 
second set of primers was used to generate fungal ITS-1 fragments that included overhanging 
adapter sequences for compatibility with Nextera XT tagmentation: next-ITS-BITS-F: 
TCGTCGGCAGCGTCACCTGCGGARGGATCA and nex-ITS-B58S3-R 
GTCTCGTGGGCTCGGGAGATCCRTTGYTRAAAGTT (adapted from Bokulich &  Mills7).  5 
µl of the previous PCR products were amplified for 10 cycles with an annealing temperature 49 
°C. Reactions were cleaned by solid-phase reversible immobilization (SPRI) using AMPure XP 
SPRI beads (Beckman Coulter, Inc.). Dual barcodes (8 bp) and Illumina sequencing adapters 
were attached using the Nextera XT Index Kit (Illumina, San Diego, CA) according to 
manufacturer’s protocols. Barcoded amplicons were quantified using the Caliper LabChip GX II 
system (Perkin Elmer, Hopkinton, USA), normalized to the same concentrations, pooled, and gel 
purified using the Qiaquick spin kit (Qiagen). Pooled amplicons were 250-bp paired-end 
sequenced using the MiSeq system (Illumina).  
Raw Illumina fastq files were demultiplexed, quality filtered, and analyzed using modules 
implemented in the Mothur software platform.8 > 35.106 raw reads were merged into 8,785,442 
paired reads. Rigorous quality filtering resulted in 7,694,074 unique paired reads with a mean 
length of 154 nt. Unique sequences were taxonomically classified by the RDP-II Naïve Bayesian 
Classifier9 using a 60% confidence threshold against the Mothur formated UNITE Database 
(Version No. 7).10 Distances between ITS library compositions were visualized in UPGMA 
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dendrograms showing Bray-Curtis statistics. The raw sequence data generated in this study will 
be deposited in the European Nucleotide Archive upon acceptance of the manuscript. 
Sequencing of bacterial 16S amplicons  
Analysis of the microbiome composition was performed by massive sequencing of the V4 
hypervariable region of the 16s rRNA gene on the illumina MiSeq sequencer. Barcoded DNA 
fragments spanning the Archaeal and Bacterial V4 hypervariable region were amplified with a 
standardizing level of template DNA (100pg) to prevent over-amplification. These amplicons, 
generated using adapted primers 533F and 806R, were bidirectionally sequenced using the MiSeq 
system (Illumina, San Diego, CA) as described previously.11 
 All data extraction, pre-processing, analysis of OTUs and classifications were performed 
using modules implemented in the Mothur software platform as in Kelder et al.12 except where 
noted below. A total of 3120791 high-quality sequences were aligned using the ‘align.seqs’ 
command and the Mothur-compatible Bacterial SILVA SEED database. A total of 6897 unique 
sequences were retrieved using this pipeline. Sequences were clustered in 1415 OTUs using 
average linkage clustering and a 97% sequence-identity threshold. Sequences were taxonomically 
classified by the RDP-II Naive Bayesian Classifier using a 60% confidence threshold. 
Community profiles were compared by Bray–Curtis dissimilarity of OTU abundance. Sequences 
were normalized to 1000 sequences per samples (subsampling method). 
 
Statistical analysis 
Fungal biomarker species that allow accurate discrimination among groups were selected 
by means of the elastic net algorithm.13 Elastic net method is naturally applicable to structured 
and high-dimensional datasets. It is a regularized method, that combines the advantages of two 
techniques: LASSO14 (sparsity, retaining the variable selection property of reducing coefficients 
to exact zero values provided by LASSO) and ridge regression (smoothness, tendency of 
shrinking coefficients to small values for correlated trending towards each other). This 
combination allows for the selection of the most important biomarkers, while taking the 
correlation (so called 'grouping effect') among them into account. 
Our statistical analysis is based on application of the adapted version of the elastic net 
algorithm (with Hinge loss function) which is specifically tailored for discriminating fungal 
species in the collected dataset. We train the model by taking the gradient of the loss that is 
estimated at each sample at a time (stochastic gradient descent learning). It consists of learning 
and stability selection modules and allows for robust and reliable identification of the biomarkers. 
Formally, our method is able to shrink coefficients to zero by imposing an L1-penalty on the 
classification coefficients; doing so allows for an easily interpretable model by viewing any 
nonzero coefficients as the predictors that have the strongest predictive power. We note that the 
elastic net algorithm allows building multivariate models, and thus, can lead to the identification 
of a group of fungal biomarkers that jointly have an effect on a differentiation among healthy 
volunteers vs normally sensitive IBS, heathy volunteers vs hypersensitive IBS, normal sensitive 
IBS vs hyper sensitive IBS patients. While the biomarkers identified by elastic net algorithm 
usually lead to statistically significant results, they can frequently be unstable. In our approach, 
we address this problem via stability selection procedure coupled with the model selection. 
Biomarker stability is reflected in the frequency that a particular biomarker was identified in 
multiple simulations on a re-randomized dataset. This measure is especially relevant for small to 
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medium sized data collections, as in this study where the number of patients diagnosed IBS with 
is limited.  
The performance measure used for a binary classification task is a Receiver-Operating-
Characteristics Area-Under-Curve (ROC AUC). The ROC can be understood as a plot of the 
probability of correctly classifying healthy volunteers vs normally sensitive IBS or heathy 
volunteers vs hypersensitive IBS or normal sensitive IBS vs hyper sensitive IBS patients. Thus, 
the AUC score of an ROC curve can be considered a measure of the predictive accuracy of the 
model.  
To avoid over-fitting, we used a 10-fold stratified cross-validation procedure over the 
training partition of the data (80%) while the remaining 20% was used as the testing dataset. 
Parameters to be selected are ratio between L1, L2 norms, and regularization parameter. Stability 
selection was performed by randomly subsampling 80% of the data 100 times. During stability 
selection procedure, all features having non-zero weighting coefficient were counted. These 
counts were normalized and converted to stability coefficients having value between 1.0 for the 
feature which was always selected and 0.0 for feature which was never selected. We used Python 
(version 2.7.8, packages Numpy, Scipy) for implementing elastic net model and the R version 
3.1.2 for visualization. 
To analyse the fungal composition of humans/rats, an unsupervised co-regularized 
spectral clustering algorithm was applied to the dataset.15, 16 In short, this multi-view clustering 
algorithm allows for identification of clusters comprised of humans/rats with similar 
fungal/microbial profiles in an unbiased and robust manner. The method stems from a recently 
proposed class of multi-view clustering algorithms17  16 that have been reported to notably 
outperform standard techniques (e.g. k-means, hierarchical clustering, etc.) in clustering accuracy 
and stability. Multi-view algorithms (closely related to cluster ensembles and consensus 
techniques) aim to combine multiple clustering hypotheses for increased accuracy and are not 
limited to a single similarity measure, thus leading to robust and reliable results. 
  
Whole mount staining mesenteric windows.  
Mouse mesenteric windows were carefully preserved and pinned down in a Sylgard dish 
(see Supplementary Figure 8A). After 30 minutes pre-incubation with 3% BSA in PBS, 
mesenteric windows were incubated with beta glucan (5 mg/ml PBS, Biotec Pharmacon) or PBS-
BSA for 30 minutes and washed. Subsequently, windows were exposed to Texas-red labeled 
avidin (30 minutes), washed, carefully removed from Sylgard dish and mounted in DAPI 
containg Vectashield mounting medium. In non-fixed tissues, avidin interacts with mast cell 
heparin of degranulating mast cells only.18   
 
Dectin-1 expression on HMC-1 cells 
The human mast cell line HMC-1 was kindly provided by Dr J.H. Butterfield (Mayo 
Clinic, Rochester, MN). Dectin-1 surface marker expression was analyzed with mouse anti 
Human Dectin-1 antibody conjugated to Alexa Fluor 647 (Serotec, Raleigh, US). Before staining, 
cells were pretreated with human Fc-receptor blocking reagent (Miltenyi Biotec, Leiden, The 
Netherlands). Data was acquired on an LSRFortessa analyzer (BD Biosciences, Breda, The 
Netherlands) and analyzed with FlowJo software (Treestar, San Carlos, US).  
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HPLC detection of histamine in HMC-1 cell supernatants. 
HMC-1 cells (106/ml) were incubated at 37°C for 10 min in HBSS with 50 µg/ml 
compound 48/80 or heat-inactivated Candida albicans (ATCC 18804, 2.5.106/ml). Vehicle 
treated cells served as negative control. After stimulation, cells were spun down and norvalin (50 
nM) was added to supernatants as internal standard. Similarly, histamine standard solutions were 
prepared by mixing 1 µM histamine with 50 nM norvaline in acetonitrile. Before detection by 
HPLC, cell culture supernatants were deproteinized by acetonitrile treatment. HPLC detection 
was performed with a Dionex Ultimate 3000 HPLC equipped with a RF 2000 fluorimetric 
detector (Dionex, Germering, Germany). Before injection, histamine was derivatized with o-
phthalaldehyde (OPA) in autosampler and injected automatically onto a BDS hypersil C18 
column (Thermo Scientific, Rockford, IL, USA) (150x4.6 mm, particle size 3 µm, 2 columns in 
tandem) equipped with a guard cartridge C 18 ODS 4x3 mm (Phenomenex, Utrecht, The 
Netherlands). Gradient elution was performed with the following solvents; A, sodium phosphate 
buffer (125 mM, pH 7), water (20:80) containing 0.5% of tetrahydrofurane; B, sodium phosphate 
buffer (125 mM, pH 7), tetrahydrofurane, acetonitrile, water (5:7:40:48). Gradient conditions 
were: 13 min (75% B), 8 min isocratic, 5 min (0% B) and elution flow was 0.7 ml/min. Detection 
wavelengths: excitation: 345 nm, emission: 485 nm. Under these conditions, the retention time 
for histamine derivative is 16.5 minutes. Results are expressed as histamine/norvaline ratio. 
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Supplementary Figure 1. Combined relative presence of Saccharomyces cerevisiae & 
Candida albicans. Intergroup differences between healthy volunteers, hypersensitive IBS and 
normally sensitive IBS. Data are mean ± SEM. *P<0.05, ***P<0.001 (Wilcoxon signed rank). 
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Supplementary Figure 2. No difference in bacterial microbiome between healthy 
volunteers, normosensitive IBS and hypersensitive IBS. Left side dendrogram shows the result 
of Bray-Curtis dissimilarity. Right side heatmap shows relative abundance of bacterial classes 
detected in individual fecal samples.   
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Supplementary Figure 3. Fecal human mycobiome signatures identified by stability 
selection. (A) Intergroup differences between normally sensitive IBS (IBS-N) and healthy 
volunteers (HV) and (B) between hypersensitive IBS (IBS-H) and IBS-N. The respective receiver 
operating characteristic (ROC) curves are depicted in (C) and (D). The area under the curves 
(AUC; 0.90 and 0.86 respectively, p<0.01 in both simulations) show good (AUC 0.8-0.9) 
discriminating quality. 
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Supplementary Figure 4. Relative response to distension of donor rats (n=4-5) used in fecal 
transplantation experiments (results of transplantation experiments are shown in Fig 2C). 
Caecum content was gathered after the last distension protocol in each group. Group 1 donors: 
maternally separated rats treated with fluconazole/nystatin. Group 2 donors: non fungicide treated 
maternally separated rats. Group 3 donors: non fungicide treated non-handled rats. (A) Visceral 
sensitivity status is depicted by area under the curve of the relative response to colorectal 
distension. (B) The same results as volume/relative response line diagrams. All data are mean ± 
SEM, n.s. not significant, *P<0.05.  
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Supplementary Figure 5. No difference in bacterial microbiome composition between non-
handled (NH), maternal separated (MS) and post fluconazole/nystatin maternal separated 
(MS+F/N) rat groups. Left side dendrogram shows the result of Bray-Curtis dissimilarity. Right 
side heatmap shows relative abundance of bacterial classes detected in individual fecal samples.   
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Supplementary Figure 6. Fecal rat mycobiome signature identified by stability selection. (A) 
Intergroup differences between nonhandled (NH) rats and maternally separated (MS) rats. The 
corresponding receiver operating characteristic (ROC) curve is depicted in (B). The area under 
the curve (AUC; 0.98) indicated outstanding (AUC>0.9) discriminating quality. 
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Supplementary Figure 7. Fecal mycobiome composition. Relative contribution class 
breakdown in human and rat feces. 
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Supplementary Figure 8. Fungal induced mast cell degranulation. (A) Exteriorized mouse 
gut with mesentery was pinned down in Sylgard dishes. Dotted lines indicate the translucent 
mesenteric windows that were incubated with (B) PBS-Bovine Serum Albumin or (C) 5 mg 
(Dectin-1 activating) particulate β-glucan/ml PBS and stained with Texas-red labeled avidin18 
and DAPI. (D) F CS staining of the human mast cell line HMC-1 showed Dectin-1 expression in 
part of the cells. (E) Shows HPLC evaluation of HMC-1 cell culture supernatants.  
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Supplementary Figure 9. Per volume line diagrams; pre water avoidance (WA) anti-fungal 
treatment of maternal separated (MS) rats. All data are mean ± SEM, n.s. not significant, 
*P<0.05, *P<0.01, n=8-9/group. Corresponding area under the curve bar diagram depicted in 
Figure 2A of the manuscript.  
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Supplementary Figure 10. Per volume line diagrams; pre water avoidance (WA) anti-fungal  
treatment of non-handled (NH) rats. All data are mean ± SEM, n.s. not significant, *P<0.05, 
n=8-9/group. Corresponding area under the curve bar diagram depicted in Figure 2A of the 
manuscript.  
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Supplementary Figure 11. Per volume line diagrams; post water avoidance (WA) anti-
fungal treatment and subsequent fungal repopulation. All data are mean ± SEM, n.s. not 
significant, *P<0.05, n=8-9/group. Corresponding area under the curve bar diagram depicted in 
Figure 2C of the manuscript.  
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Supplementary Figure 12. Per volume line diagrams; rats used in mycobiome evaluations. 
All data are mean ± SEM, n.s. not significant, *P<0.05 (n=7-8). Corresponding area under the 
curve bar diagram depicted in Figure 3A of the manuscript.  
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Supplementary Figure 13. Per volume line diagrams; post water avoidance (WA) treatment 
with Syk inhibitor. All data are mean ± SEM, n.s. not significant, *P<0.05, **P<0.01, n=8-
9/group. Corresponding area under the curve bar diagram depicted in Figure 6A of the 
manuscript.  
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Supplementary Figure 14. Per volume line diagrams; peri water avoidance (WA) treatment 
with soluble β-glucans (SBG). All data are mean ± SEM, n.s. not significant, *P<0.05, 
**P<0.01, n=8-9/group. Corresponding area under the curve bar diagram depicted in Figure 6B 
of the manuscript.   
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Supplementary Figure 15. Per volume line diagrams; post  water avoidance (WA) 
treatment with soluble β-glucans (SBG). All data are mean ± SEM, n.s. not significant, 
*P<0.05, **P<0.01, n=8-9/group. Corresponding area under the curve bar diagram depicted in 
Figure 6C of the manuscript.   
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 Hypersensitivea 
IBS n=8 
Normosensitivea 
IBS n=12 
Healthy 
controls n=18 
Energy (kJ/day) 
Total protein (g/day) 
Total fat g/day) 
Total carbohydrates (g/day) 
Fibers (g/day) 
8648.9±3427.5 
69.6±25.3 
79.5±38.6 
231.25±99.3 
21.13±9.4 
7997.2±2025.2 
68.9±22.8 
76.83±28.3 
210.8±45.4 
18.8±6.7 
10133,4±2991.0* 
86.9±29.7* 
93.6±28.3* 
267,8±84.7* 
27.7↑9.6* 
 
Supplementary Table 1. Dietary intake based on validated food frequency questionnaire. 
a)Patient data only available for subgroups. *P<0.05 for Healthy controls vs IBS total 
(hypersensitive+normosensitive) as tested by ANOVA. No difference was found between hyper- 
versus normosensitive IBS patients. 
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Supplementary Table 2. Mycobiome species present in rat and human fecal samples. The 
list   of human mycobiome species was taken from the stability selection presented in figure 1C 
(relative weights Irritable Bowel Syndrome-hypersensitive vs healthy volunteer). The list of rat 
mycobiome species was taken from stability selection presented in figure S3 (relative weights 
maternal separated vs non-handled rats).  
 
Human mycobiome Present in rat and human Rat mycobiome 
Kazachstania telluris Davidiella tassiana Lasiospaeriaceae spp. 
Penicillium spinulosum Vishniacozyma victoriae Fusarium fujikuroi complex 
Penicillium commune Alternaria metachromatica uncultured Ascochyta 
Aspergillus section Nidulantes Epicoccum nigrum Unclassified 
Rhodosporidiobolus colostri Trichomerium gloeosporum Acremonium zeae 
Cyberlindnera c.f. jadinii 
Aspergillus section 
Aspergillus Papiliotrema laurentii 
Candida quercitrusa Verticillium leptobactrum Microdochium phragmitis 
Apiotrichum gracile Candida albicans Fusarium poae 
Acremonium spp. 
Aspergillus section 
Nidulantes Rhodotorula mucilaginosa 
Penicillium roquefortii Wallemia muriae Wickerhamomyces bovis 
Saccharomyces bulderi Sporobolomyces roseus Cryptococcus sp 
Agaricus bisporus Alternaria alternata Acremonium sp 
Candida humilis Monographiella nivalis Aspergillus section Aspergillus 
Wickerhamomyces onychis 
 
Claviceps purpurea 
Candida parapsilosis 
 
Wallemia sebi 
Debaryomyces prosopidis 
 
Pleospora spp. 
Meyerozyma guilliermondii 
 
Eudarluca caricis 
Saccharomyces cerevisiae 
 
Microdochium nivale var. Nivale 
Phoma spp. 
 
Cladosporium cladosporioides 
complex 
Rhodotorula mucilaginosa 
 
Capnodiales spp. 
Penicillium section Chrysogena 
 
Monographella albescens 
Suillus luteus 
 
Holtermanniella festucosa 
Cladosporium cladosporioides 
complex 
  Rodentomyces reticulatus 
  Fusarium oxysporum complex 
  Acremonium spp. 
  Kazachstania barnettii 
  Torulaspora delbrueckii 
  Cystofilobasidium infirmominiatum 
  Gloeophyllum trabeum 
  Candida glaebosa 
  Candida tropicalis 
  Candida solani 
  unclassified 
  Kazachstania turicensis 
  
